Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥238.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥29.0bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥29.1bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax¥68.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.3bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥45.3bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥19.6bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥491.5bnat 2024-09-30Cons.Assets IFRS
Total assets¥490.8bnat 2024-03-31Cons.Assets IFRS
Total assets¥461.0bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥127.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥124.1bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥364.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥366.7bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥349.5bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥351.9bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥148.1bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥149.7bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥23.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥58.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥39.5bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥12.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥9.4bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.682023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥25.42024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥66.632023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio71.1%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥18m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥100m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2024-04-01 → 2024-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2024-04-01 → 2024-09-30¥40.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥28m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.0bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.6bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥123.7bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥1.9bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥30.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 642
ItemContextValueUnit
Finance income ope cf IFRSCurrentYTDDuration-1133000000JPY
Finance costs ope cf IFRSPrior1YTDDuration157000000JPY
Finance costs ope cf IFRSCurrentYTDDuration1041000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration-284000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-1308000000JPY
Change in financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration-1367000000JPY
Change in financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration512000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration642000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration1908000000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration800000000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration-2476000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSPrior1YTDDuration172000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSCurrentYTDDuration139000000JPY
Decrease increase in other current assets ope cf IFRSPrior1YTDDuration-264000000JPY
Decrease increase in other current assets ope cf IFRSCurrentYTDDuration-565000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-541000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-1309000000JPY
Subtotal ope cf IFRSPrior1YTDDuration37904000000JPY
Subtotal ope cf IFRSCurrentYTDDuration31019000000JPY
Dividends received ope cf IFRSPrior1YTDDuration478000000JPY
Dividends received ope cf IFRSCurrentYTDDuration936000000JPY
Interest received ope cf IFRSPrior1YTDDuration843000000JPY
Interest received ope cf IFRSCurrentYTDDuration1133000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-156000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-300000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-12248000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-9193000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration26821000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration23595000000JPY
Payments into time deposits inv cf IFRSPrior1YTDDuration-17195000000JPY
Payments into time deposits inv cf IFRSCurrentYTDDuration-16333000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSPrior1YTDDuration14606000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSCurrentYTDDuration12253000000JPY
Purchase of financial assets measured at fair value inv cf IFRSPrior1YTDDuration-1613000000JPY
Purchase of financial assets measured at fair value inv cf IFRSCurrentYTDDuration-1590000000JPY
Proceeds from sale of financial assets measured at fair value inv cf IFRSPrior1YTDDuration402000000JPY
Proceeds from sale of financial assets measured at fair value inv cf IFRSCurrentYTDDuration643000000JPY
Purchase of financial assets measured at amortised cost inv cf IFRSPrior1YTDDuration-JPY
Purchase of financial assets measured at amortised cost inv cf IFRSCurrentYTDDuration-752000000JPY
Proceeds from sale or redemption of financial assets measured at amortised cost inv cf IFRS IFRSPrior1YTDDuration-JPY
Proceeds from sale or redemption of financial assets measured at amortised cost inv cf IFRS IFRSCurrentYTDDuration1369000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-4338000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-2512000000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-1048000000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-1122000000JPY
Payments for leasehold deposits and guarantee deposits inv cf IFRSPrior1YTDDuration-191000000JPY
Payments for leasehold deposits and guarantee deposits inv cf IFRSCurrentYTDDuration-195000000JPY
Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRSPrior1YTDDuration265000000JPY
Proceeds from collection of leasehold deposits and guarantee deposits inv cf IFRSCurrentYTDDuration87000000JPY
Payments for loans receivable inv cf IFRSPrior1YTDDuration-1000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass